Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 685 clinical trials
An Open-Label, Phase 1/2 Study Evaluating AVM0703 in Patients With Lymphoid Malignancies (WWRD Study)

This is an open-label, Phase 1/2 study designed to characterize the safety, tolerability, Pharmacokinetics(PK), and preliminary antitumor activity of AVM0703 administered as a single intravenous (IV) infusion to patients with lymphoid malignancies.

  • 7 views
  • 24 Oct, 2022
  • 7 locations
Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Patients (FIL_RENOIR12)

A randomized phase III multicenter trial assessing efficacy and toxicity of a combination of Rituximab and Lenalidomide (R2) vs Rituximab alone as maintenance after chemoimmunotherapy with Rituximab-chemotherapy (R-CHT) for relapsed/refractory FL patients not eligible for autologous transplantation (ASCT)

tumor burden
rituximab
neutrophil count
platelet count
lenalidomide
  • 58 views
  • 04 Oct, 2022
  • 28 locations
Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents

Acute lymphoblastic leukemia (ALL) is the most common cancer diagnosed in children. The cancer comes from a cell in the blood called a lymphocyte. Normal lymphocytes are produced in the bone

corticosteroids
dexamethasone
doxorubicin
adult t-cell leukemia/lymphoma
cytarabine
  • 26 views
  • 20 Jun, 2022
  • 9 locations
A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

In this study, adults with newly-diagnosed Philadelphia Chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) will receive first-line therapy of ponatinib or imatinib. The main aim

dexamethasone
residual tumor
cytarabine
methotrexate
minimal residual disease
  • 87 views
  • 07 Oct, 2022
  • 88 locations
Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2015 (ALL-MB 2015)

QUESTIONS AND OBJECTIVES OF ALL-MB 2015 STUDY Will the new risk group stratification (especially of T-ALL) to improve overall and event-free survival? Will the new protocol is effective and feasible in patients older than 15 years, and especially in young adults? Whether the intermittent dexamethasone administration in induction will result …

dexamethasone
childhood all
adult t-cell leukemia/lymphoma
daunorubicin
lymphoid leukemia
  • 179 views
  • 23 Jan, 2021
  • 59 locations
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

improve the cure rate and quality of life of children with acute lymphoblastic leukemia (ALL) and acute lymphoblastic lymphoma (LLy). Primary Therapeutic Objectives: To improve the

dexamethasone
doxorubicin
adult t-cell leukemia/lymphoma
residual tumor
clofarabine
  • 308 views
  • 07 Oct, 2022
  • 7 locations
Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017

The understanding of acute lymphoblastic leukemia (ALL) in childhood and adolescence has largely changed due to extensive genetic research in recent years: ALL is now considered to be a very

dexamethasone
doxorubicin
adult t-cell leukemia/lymphoma
residual tumor
daunorubicin
  • 897 views
  • 13 Feb, 2022
  • 93 locations
A French Protocol for the Treatment of Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents (CAALL-F01)

A still major question in the field of acute lymphoblastic leukemia (ALL) in children - an extremely heterogeneous disease though curable in 80-90% of children and 70-80% of the adolescents - is

lymphoid leukemia
asparaginase
pegaspargase
induction therapy
  • 0 views
  • 26 Jan, 2022
  • 28 locations
A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

This is a Phase 2, open-label, multicenter study, evaluating the efficacy of venetoclax in participants with relapsed or refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma

venetoclax
measurable disease
TP53
lymphadenopathy
chronic lymphocytic leukemia refractory
  • 229 views
  • 04 Oct, 2022
  • 30 locations
A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-314) (BRUIN-CLL-314)

The purpose of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL. Participants may or may not have already had treatment for their cancer. Participation could last up to six years.

cancer
ibrutinib
neutrophil count
chronic lymphocytic leukemia
lymphoma
  • 0 views
  • 20 Oct, 2022
  • 25 locations